These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7926967)

  • 1. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia.
    Michelutti A; Michieli M; Damiani D; Melli C; Geromin A; Russo D; Fanin R; Baccarani M
    Haematologica; 1994; 79(3):200-4. PubMed ID: 7926967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia.
    Damiani D; Michieli M; Michelutti A; Fanin R; Russo D; Baccarani M
    Leuk Lymphoma; 1995 Apr; 17(3-4):289-94. PubMed ID: 8580798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of p53 protein and MDR functional phenotype in leukemias: the predominant association in chronic myeloid leukemia.
    Cavalcanti GB; Vasconcelos FC; Pinto de Faria G; Scheiner MA; de Almeida Dobbin J; Klumb CE; Maia RC
    Cytometry B Clin Cytom; 2004 Sep; 61(1):1-8. PubMed ID: 15351976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
    Bodey B; Taylor CR; Siegel SE; Kaiser HE
    Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
    Giles FJ; Kantarjian HM; Cortes J; Thomas DA; Talpaz M; Manshouri T; Albitar M
    Cancer; 1999 Sep; 86(5):805-13. PubMed ID: 10463979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia.
    Weide R; Dowding C; Paulsen W; Goldman J
    Leukemia; 1990 Oct; 4(10):695-9. PubMed ID: 1976871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia.
    Savignano C; Geromin A; Michieli M; Damiani D; Michelutti A; Melli C; Fanin R; Baccarani M
    Haematologica; 1993; 78(5):261-3. PubMed ID: 7906239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
    Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
    Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cause of death, survival, and prognostic factors in a series of 98 patients with chronic myeloid leukemia].
    Jonte F; Fernández-Fuertes F; Cecchini C; Luño E; Ordóñez A; Fernández C; Suárez P; Lausín A; Fernández J
    Sangre (Barc); 1992 Oct; 37(5):351-4. PubMed ID: 1293774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
    Lanza F; Bi S; Castoldi G; Goldman JM
    Leukemia; 1993 Oct; 7(10):1570-5. PubMed ID: 7692192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine.
    Russo D; Michelutti A; Melli C; Damiani D; Michieli MG; Candoni A; Zhou DC; Marie JP; Zittoun R; Baccarani M
    Leukemia; 1995 Mar; 9(3):513-6. PubMed ID: 7885049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric determination of the multidrug-resistant phenotype in acute leukemia.
    Maslak P; Hegewisch-Becker S; Godfrey L; Andreeff M
    Cytometry; 1994 Sep; 17(1):84-93. PubMed ID: 8001461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone marrow morphologic features in patients treated with imatinib for Philadelphia chromosome positive chronic myeloid leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Shi HL; Lu Y; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2004 Mar; 25(3):158-62. PubMed ID: 15182585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
    González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
    Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
    Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
    Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia.
    Carulli G; Petrini M; Marini A; Vaglini F; Caracciolo F; Grassi B
    Haematologica; 1990; 75(6):516-21. PubMed ID: 1982999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.